Abstract Number: 1847 • 2017 ACR/ARHP Annual Meeting
The IgG4:IgG RNA Ratio in Peripheral Blood Perfectly Differentiates Active Disease from Remission in Granulomatosis with Polyangiitis. a New Disease Activity Marker?
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is characterized by vasculitis in lungs, kidneys and the ear, nose and throat region. Regular monitoring and treatment adjustments are…Abstract Number: 2346 • 2017 ACR/ARHP Annual Meeting
Chemokine Ligand 9 (CXCL9) [Monokine Induced By Gamma Interferon (MIG)] As a Predictor of Active Disease Status in Localized Scleroderma
Background/Purpose: Localized scleroderma (LS) is a fibrotic autoimmune disease of the skin and underlying tissues which can lead to disfiguring sequlea, especially in childhood-onset. Untreated…Abstract Number: 2550 • 2017 ACR/ARHP Annual Meeting
A New and Simpler Tool for Global Psoriatic Arthritis Assessment: Simplified Composite Psoriatic Disease Activity Index (sCPDAI)
Background/Purpose: The heterogeneity of psoriatic arthritis ( PsA) that includes a possible combination of axial disease, peripheral arthritis, enthesitis, dactylitis, skin and nail involvement, makes…Abstract Number: 2917 • 2017 ACR/ARHP Annual Meeting
Neutrophil Activation in Rheumatoid Arthritis – Potential Biomarkers of Disease Activity and Severity
Background/Purpose: Neutrophil activation is associated with inflammation and autoimmunity, including rheumatoid arthritis (RA), where neutrophil infiltration to joints participates in tissue destruction and development of…Abstract Number: 163 • 2017 ACR/ARHP Annual Meeting
Fibromyalgia Patients Identify More Causes of Disease Flare Ups Than RA Patients
Background/Purpose: We compared patients with the Fibromyalgia Syndrome (FMS) and Rheumatoid Arthritis (RA) patients with respect to stresses that the patients believe may have caused…Abstract Number: 699 • 2017 ACR/ARHP Annual Meeting
Impact of Anti-RBP Antibodies on Disease Activity and Quality-of-Life in Immunosuppressant Naive Systemic Lupus Erythematosus
Background/Purpose: There is a lack of phenotypic data on SLE patients who have never been on immunosuppressive therapy. Anti-RNA binding protein (anti-RBP) antibodies (anti-Smith, anti-RNP,…Abstract Number: 1241 • 2017 ACR/ARHP Annual Meeting
Understanding Differences in Patient Definitions of RA Flares Using Omeract Core Domains
Background/Purpose: Flare is an important, distinct feature of RA, often rendering patients immobile and contributing to a poor quality of life. Recently, there has been…Abstract Number: 1552 • 2017 ACR/ARHP Annual Meeting
Persistency of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: There are limited data regarding persistency of TNF inhibitor (TNFi) therapies in patients with ankylosing spondylitis (AS) treated in real-world clinical practice. The objective…Abstract Number: 1848 • 2017 ACR/ARHP Annual Meeting
NMR-Based Serum Metabolomics of Patients with Takayasu Arteritis (TA) and Relationship with Disease Activity
Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis of unknown pathogenesis. The current serological and radiological parameters used to assess disease activity are not…Abstract Number: 2353 • 2017 ACR/ARHP Annual Meeting
The Relationship between Disease Activity, VEGF and E-Selectin Levels with Arterial Stiffness in Rheumatic Patients Treated with Biological Agents
Background/Purpose: Rheumatic diseases are chronic-inflammatory disease associated with endothelial damage, changes in vascular permeability and plaque formation. VEGF and E-selectin play an important role in…Abstract Number: 2582 • 2017 ACR/ARHP Annual Meeting
Compliance and Persistence with Hydroxychloroquine in Patients with Systemic Lupus Erythematosus
Compliance and persistence with hydroxychloroquine in patients with systemic lupus erythematosusBackground/Purpose: Lifelong treatment with hydroxychloroquine (HCQ) is now recommended for all patients with systemic lupus…Abstract Number: 2958 • 2017 ACR/ARHP Annual Meeting
Validation of Flare Criteria for Children and Adolescents with Systemic Lupus Erythematosus
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is characterized by changing disease activity: episodes of improvement are often followed by episodes of worsening, i.e. flares. Considering…Abstract Number: 241 • 2017 ACR/ARHP Annual Meeting
Histological and Clinical Correlates of Ultrasound Measures of Joint Inflammation: Analysis of RA Tissue Obtained By Ultrasound Guided Biopsy in Phase 1 of the Accelerating Medicines Partnership RA Network
Background/Purpose: The AMP-RA network applies cutting edge technologies to the study of tissue obtained by ultrasound guided synovial biopsy from patients with rheumatoid arthritis (RA).…Abstract Number: 713 • 2017 ACR/ARHP Annual Meeting
Long-Term Outcomes in Prolonged Low Disease Activity Are Comparable to Complete Clinical Remission in Systemic Lupus Erythematosus
Background/Purpose: Prolonged clinical remission is a desirable, though rare outcome in systemic lupus erythematosus (SLE). We recently showed that low disease activity (LDA) state confers…Abstract Number: 1251 • 2017 ACR/ARHP Annual Meeting
Chinese Patient Reported Index with Rheumatoid Arthritis (CPRI-RA): Reliability, Validity and Agreement with DAS28 and HAQ
Background/Purpose: The use of patient reported outcomes(PROs) has become increasingly popular in the chronic disease management, disease monitoring and the assessment of drug efficacy. However,…
- « Previous Page
- 1
- …
- 63
- 64
- 65
- 66
- 67
- …
- 102
- Next Page »